MiNK Therapeutics, Inc. (INKT) Stock Score, Valuation & Financial Research

MiNK Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INKT

MiNK Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.70. These figures are a research snapshot, not a buy or sell recommendation.

What MiNK Therapeutics, Inc. does

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MiNK Therapeutics is a clinical-stage biopharmaceutical company that generates no commercial revenue. Its business model relies on research and development of allogeneic, ex-vivo expanded invariant natural killer T (iNKT) cell therapies, funded through capital raises and potential future licensing or collaboration agreements.

Products and services

  • The company develops a pipeline of engineered iNKT cell therapies, including lead candidates MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT), designed to treat cancer and immune-mediated diseases.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Autonomous Therapeutics — Research collaboration to evaluate encrypted RNA technologies in combination with MiNK-215 and agenT-797 in metastatic solid tumor models. Source
  • Immunoscape, Inc. — Collaboration to discover and develop TCR-based therapies across multiple immune cell modalities. Source
  • C-Further — Collaboration to advance PRAME-targeted iNKT cell therapy for pediatric cancers. Source

Business strengths to evaluate

  • Proprietary allogeneic iNKT cell platform Source

Business risks and research considerations

  • Substantial doubt regarding ability to continue as a going concern Source
  • Dependence on third-party manufacturers Source

Sources: Company research source · C-Further

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INKT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.70
Market capitalization:
58.29M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -11.36M
Free cash flow:
USD -5.93M
Cash:
USD 8.81M
Total debt:
USD 5.18M
EPS:
USD -2.39

What stands out

  • Free cash flow is USD -5.93M, negative for the stored period.
  • The balance sheet shows USD 8.81M of cash versus USD 5.18M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.63M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INKT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can INKT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is INKT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for INKT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of INKT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research INKT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.